865 Immunotherapy in advanced Merkel cell carcinoma: Frequent responses but a potentially concerning recurrence rate after therapy discontinuation
Merkel cell carcinoma (MCC) is an aggressive skin cancer that often recurs. MCC tumors can respond to PD-1 pathway inhibitors rapidly, however, it is unclear how often these responses persist after discontinuation of therapy. We retrospectively assessed 159 persons with advanced MCC treated with first-line anti-PD-(L)1 agents. Non-responders were defined as those with progressive disease (PD) or stable disease (SD), while responders had partial response (PR), or complete response (CR), based on clinician assessment.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Y. Moshiri, N. Alexander, T. Akaike, C. Doolittle-Amieva, T. Pulliam, L. Zaba, P. Nghiem Tags: Translational Studies Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Dermatology | Immunotherapy | Merkel Cell Carcinoma | Skin | Skin Cancer | Study